



Shenzhen Lvshiyuan Biotechnology Co., Ltd.

GF102B1

Revision Date: 18/11/2020

SARS-CoV-2 Antigen Rapid Test Kit (Colloidal Gold) Instruction for Use

Shenzhen Lvshiyuan Biotechnology Co., Ltd.

Product Name

SARS-CoV-2 Antigen Rapid Test Kit (Colloidal Gold)

Package and Specification

25 Tests/box (1Test/Bag ×25 Bags)

Intended Use

For in vitro qualitative detection of SARS-CoV-2 nucleocapsid antigen in nasal swab specimens directly from individuals who are suspected of COVID-19 by their healthcare provider within the first 5 days after onset of symptoms. This test is only provided for use by clinical laboratories or healthcare workers for point-of-care testing, not for at-home testing.

Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2 or 2019-nCoV) is an enveloped non-segmented positive-sense RNA virus. It is the cause of coronavirus disease 2019 (COVID-19), which is contagious in humans. SARS-CoV-2 has several structural proteins including spike (S), envelope (E), membrane (M), and nucleocapsid (N).

The antigen is generally detectable in upper respiratory samples during the acute phase of infection. Positive results indicate the presence of viral antigens, but the clinical correlation with patient history and other diagnostic information is necessary to determine infection status. Positive results do not rule out a bacterial infection or co-infection with other viruses. The agent detected may not be the definite cause of disease.

Negative results should be treated as presumptive, which do not rule out SARS-CoV-2 infection and should not be used as the sole basis for treatment or patient management decisions, including infection control decisions. Negative results should be considered in the context of a patient's recent exposures, history, and the presence of clinical signs and symptoms consistent with COVID-19, and confirmed with a molecular assay, if necessary, for patient management.

For in vitro diagnostic use only. For professional use only.

Test Principle

Green Spring® SARS-CoV-2 Antigen Rapid Test Kit (Colloidal Gold) uses an immunocapture method; it is designed to detect the presence or absence of SARS-CoV-2 nucleocapsid proteins in respiratory samples from patients with signs and symptoms of infection that are suspected of COVID-19.

Key components: the anti-nucleocapsid protein antibody labeled by colloidal gold, the nitrocellulose membrane coated with anti-nucleocapsid protein antibody and goat anti-mouse IgG antibody.

When specimens are processed and added to the test device, SARS-CoV-2 antigens present in the specimen bind to antibodies conjugated to colloidal gold in the test strip. The antigen-conjugate complexes migrate across the test strip to the reaction are captured by a line of antibodies bound on the membrane. A color band will show up when antigen-conjugate is deposited at the Test “T” position and the Control “C” position on the device.

Component

Component	25Tests/Kit	Main components
Test device	25 Tests/Kit (1Test/bag ×25 Bags)	The anti-nucleocapsid protein antibody labeled by colloidal gold, the nitrocellulose membrane coated with anti-nucleocapsid protein antibody and goat anti-mouse IgG antibody.
Desiccant	25 packs	Silica Gel
Buffer	2 bottles, each with 7ml extraction buffer / 25 bottles each with 0.5ml extraction buffer	Detergent solution
Extraction tube	25 single-use reaction tubes, each with 1x nozzle cap	/
Specimen sampling swabs	25 sterile, single-use specimen sampling swabs	/
Package Insert	1 Instruction for Use	/

Storage and Stability

1. Store at 2~30°C in the sealed pouch up to the expiration date and the validity is tentatively 12 months. Do not freeze.
2. The test cassette should be used within 1 hour after taking out from the aluminum foil bag.
3. Keep away from sunlight, moisture, and heat.

Specimen Collection and Handling

1. Specimen Collection and Preparation

Acceptable specimens for testing with this kit include nasal swab specimens obtained by the dual nares collection method. Correct specimen collection and preparation methods must be followed. Specimens obtained early during symptom onset will contain the highest viral titers; specimens obtained after five days of symptoms are more likely to produce negative results when compared to an RT-PCR assay. Inadequate specimen collection, improper specimen handling and/or transport may yield a falsely negative result; therefore, training in specimen collection is highly recommended due to the importance of specimen quality for generating accurate test results.

2. Specimen Transport and Storage

Freshly collected specimens should be processed as soon as possible, but no later than one hour after specimen collection. Correct specimen collection and preparation methods must be followed.

3. Nasal Swab Specimen Collection

- 1) Insert the swab into one nostril of the patient. The swab tip should be inserted up to 2.5 cm (1 inch) from the edge of the nostril. Roll the swab 5 times along the mucosa inside the nostril to ensure that both mucus and cells are collected.
- 2) Using the same swab, repeat this process for another nostril to ensure that adequate samples are collected from both nasal cavities.
- 3) Withdraw the swab from the nasal cavity. The sample is now ready for processing of using the kit.



●DOs and DON'Ts of Sample Collection

1. Do collect samples as soon as possible after the onset of symptoms.
2. Do test samples immediately.
3. Use only swabs provided in the kit.

Test Procedure

The test kit and specimen must be kept to room temperature (15~30°C) before testing. The kit is only intended for nasal swab specimens that are collected and tested directly (i.e., swabs that have NOT been placed in transport media). The kit includes a pre-diluted processing reagent in a ready-to-use “unitized” tube. This kit IS NOT INTENDED for testing liquid samples such as a wash or aspirate samples or swabs in transport media as results can be compromised by over dilution.


1. Tear off the foil pouch, take out the test strip/cassette and place the test kit on a clean and level surface.
2. Freshly collected specimens should be processed within 1 hour.
3. Label one test device and one extraction tube for each specimen or control to be tested.
4. Place the labeled extraction tube(s) in a rack in the designated area of the workspace.
5. Twist off the top of the buffer bottle, slowly titrate 10 drops (0.3-0.5mL) into the extraction tube when 7mL/bottle buffer is used;
Or dispense entire buffer into the extraction tube when 0.5mL/bottle buffer is used.
6. Insert the swab into the tube and plunge the swab up and down in the fluid for a minimum of 10 seconds, then hold the swab against the bottom of the tube and rotate 3 turns, taking care not to splash contents out of the tube.
7. Remove the swab while squeezing the sides of the tube to extract the liquid from the swab.
8. Press the nozzle cap firmly onto the extraction tube containing the processed sample

(threading or twisting is not required). Mix thoroughly by swirling or flicking the bottom of the tube.

NOTE: Do not use tubes or tips from any other product, or from other manufacturers.

9. Gently squeeze the ridged body of the tube, dispensing two (2) drops of the processed specimen into the sample well.

10. Read the test results between 15 and 20 minutes. Do not read the results after 20 minutes.



Interpretation of Test Results


1. Positive

Two lines appear. A colored line should be in the control line region (C), a colored line appears in the test line (T) region. Positive results indicate the presence of viral antigens, but the clinical correlation with patient history and other diagnostic information is necessary to determine infection status. Positive results do not rule out a bacterial infection or co-infection with other viruses. The agent detected may not be the definite cause of disease.

2. Negative

Only one colored control line appears. Negative results are presumptive. Negative test results do not preclude infection and should not be used as the sole basis for treatment or other patient management decisions, including infection control decisions, particularly in the presence of clinical signs and symptoms consistent with COVID-19, or in those who have been in contact with the virus. It is recommended that these results be confirmed by a molecular testing method, if necessary, for patient management.

Result determination time: The result should be judged within *15~20 minutes* after the sample is added into the sample well, and the result displayed after *20 minutes* is invalid.



3. Internal Quality Control Procedure

Each Test Cassette device has a built-in control. A red colored line in the detection window at the Control Line can be considered an internal positive procedural control. The Control Line will appear if the test procedure has been correctly performed. If the Control Line does not appear, the test is invalid. Insufficient buffer volume or incorrect procedural techniques are the most likely reasons for Control Line failure. Review the procedure and repeat the procedure with a new test cassette. If the problem persists, discontinue using the test kit immediately and contact your local distributor.

Limitations of Test Method

1. This product is only suitable for a qualitative test and auxiliary diagnosis.
2. The test results are only for clinical reference and should not be the only basis for clinical diagnosis and treatment. The clinical management of patients should be considered in combination with their symptoms, physical signs, medical history, other laboratory tests, therapeutic reaction, and epidemiological information.
3. Users should test specimens as quickly as possible after specimen collection.
4. Positive test results do not rule out co-infections with other pathogens.
5. Results from the test should be correlated with the clinical history, epidemiological data, and other data available to the clinician evaluating the patient.
6. A false-negative test result may occur if the level of viral antigen in a sample is below the detection limit of the test or if the sample was collected or transported improperly; therefore, a negative test result does not eliminate the possibility of SARS-CoV-2 infection.
7. The amount of antigen in a sample may decrease as the duration of illness increases. Specimens collected after day 5 of illness are more likely to be negative compared to an

RT-PCR assay.

8. Failure to follow the test procedure may adversely affect test performance and/or invalidate the test result.
9. The contents of this kit are to be used for the qualitative detection of SARS-CoV-2 antigens from nasal swab specimens only.
10. The kit performance depends on antigen load and may not correlate with other diagnostic methods performed on the same specimen.
11. Negative test results are not intended to rule in other non-SARS-CoV-2 viral or bacterial infections.
12. Positive and negative predictive values are highly dependent on prevalence rates. Positive test results are more likely to represent false-positive results during periods of little/no SARS-CoV-2 activity when disease prevalence is low. False-negative test results are more likely when the prevalence of disease caused by SARS-CoV-2 is high.
13. This device has been evaluated for use with human specimen material only.
14. Monoclonal antibodies may fail to detect or detect with less sensitivity, SARS-CoV-2 viruses that have undergone minor amino acid changes in the target epitope region.
15. The performance of this test has not been evaluated for use in patients without signs and symptoms of respiratory infection and performance may differ in asymptomatic individuals.
16. The sensitivity of the test after the first five days of the onset of symptoms has been demonstrated to decrease as compared to a RT-PCR SARS-CoV-2 assay.
17. Negative results should be treated as presumptive and confirmed with an FDA authorized molecular assay, if necessary, for clinical management, including infection control.
18. Specimen stability recommendations are based upon stability data from influenza testing and performance may be different from SARS-CoV-2. Users should test specimens as quickly as possible after specimen collection, and within one hour after specimen collection.
19. The validity of the kit has not been proven for identification/confirmation of tissue culture isolates and should not be used in this capacity.

Performance Characteristics

1. Clinical Performance

The performance of the kit was established with 150 direct nasal swabs prospectively collected and enrolled from individual symptomatic patients (within 5 days of onset) who were suspected of COVID-19. As with all antigen tests, performance may decrease as days since symptom onset. Samples were collected by qualified personnel in China.

Nasal swabs were collected following the dual nares method and handled as described in this instruction. Specimens were frozen within 30 minutes of collection and stored until tested. All specimens within a pre-specified date range were selected and then sequentially tested in a blinded fashion.

The performance of the kit was compared to the results of a nasopharyngeal or oropharyngeal swab tested with a commercialized molecular assay.

The kit showed 90% of sensitivity and 99% of specificity.

Table 1. Clinical Study Results from symptom onset

Reagent test results	PCR Comparator		Subtotal
	Positive	Negative	
Positive	45	1	46
Negative	5	99	104
Subtotal	50	100	150

2. Assay Cross-Reactivity

Cross-Reactivity: There was no cross-reaction with potential cross-reactive substances except SARS-coronavirus.

Table 2: Cross-reactivity Results

Potential Cross-Reactant	Concentration Tested	Cross-Reactivity (Yes/No)
Influenza A	1.6 x 10 ⁵ TCID ₅₀ /mL	NO
Influenza B	1.6 x 10 ⁵ TCID ₅₀ /mL	NO
Human coronavirus HKU1	1.6 x 10 ⁵ TCID ₅₀ /mL	NO
Human coronavirus OC43	1.6 x 10 ⁵ TCID ₅₀ /mL	NO
Haemophilus influenzae	2.2x 10 ⁵ TCID ₅₀ /mL	NO
MERS-coronavirus	2.1 x 10 ⁵ TCID ₅₀ /mL	NO
SARS-coronavirus	3.2 x 10 ⁵ PFU/mL	YES
Adenovirus C1	1.5 x 10 ⁵ TCID ₅₀ /mL	NO
Adenovirus 71	1.5 x 10 ⁵ TCID ₅₀ /mL	NO

Candida albicans	4.2 x 10 ⁵ CFU/mL	NO
Respiratory syncytial virus	5.1 x 10 ⁵ TCID ₅₀ /mL	NO
Enterovirus	5.4 x 10 ⁵ TCID ₅₀ /mL	NO
Malaria	2.2 x 10 ⁶ CFU/mL	NO
Dengue	1.2 x 10 ⁵ TCID ₅₀ /mL	NO
Human coronavirus NL63	1.7x 10 ⁵ TCID ₅₀ /mL	NO
Human coronavirus 229E	2.2 x 10 ⁵ TCID ₅₀ /mL	NO
Streptococcus pneumoniae	1.1 x 10 ⁶ CFU/mL	NO
Pneumocystis jirovecii (PJP)	1.0 x 10 ⁵ TCID ₅₀ /mL	NO
Legionella pneumophila	1.4 x 10 ⁶ CFU/mL	NO
Chlamydia pneumoniae	1.1 x 10 ⁶ IFU/mL	NO
Human Metapneumovirus (hMPV)	1.1 x 10 ⁵ TCID ₅₀ /mL	NO
Parainfluenza virus 1	1.0 x 10 ⁵ TCID ₅₀ /mL	NO
Parainfluenza virus 2	1.0 x 10 ⁵ TCID ₅₀ /mL	NO
Parainfluenza virus 3	3.5 x 10 ⁵ TCID ₅₀ /mL	NO
Parainfluenza virus 4	1.4 x 10 ⁵ TCID ₅₀ /mL	NO
Rhinovirus	1.3 x 10 ⁵ PFU/mL	NO
Mycoplasma pneumoniae	1.8 x 10 ⁶ CFU/mL	NO
Bordetella pertussis	1.5 x 10 ⁶ CFU/mL	NO
Mycobacterium tuberculosis	1.0 x 10 ⁶ CFU/mL	NO
Pooled human nasal wash-representative of normal respiratory microbial flora	100%	NO
Streptococcus pyogenes	1.0 x 10 ⁶ CFU/mL	NO

3. Potentially Endogenous Interfering Substances

SARS-CoV-2 Antigen nasal swab samples were spiked with one of the following substances to specified concentrations and tested in multiple replicates. No false positivity or false negativity was found with the following:

Interfering substances	Concentration	Interfering substances	Concentration
Whole Blood	5%	Naso GEL(Nei Med)	6%v/v
Fluticasone Propionate	4%v/v	Mucin	0.54%
CVS Nasal Drops (Phenylephrine)	17%v/v	Ricola(Menthol)	1.6mg/mL
Tamiflu(Oseltamivir Phosphate)	6mg/ml	Afrin(Oxymetazoline)	14%v/v
Sucrets(Dyclonin/Menthol)	1.4 mg/mL	CVC Nasal Spray(Cromolyn)	16%v/v
Chloraseptic(Menthol/Benzocaine)	1.8 mg/mL	Nasal Gel(Oxymetazoline)	9%v/v
Homeopathic(Alkalol)	1:10dilution	Mupirocin	12 mg/mL
Ore Throat Phenol Spray	16%v/v	Fisherman's Friend	1.3mg/ml
Tobramycin	5 µg/mL	Zicam	4%v/v

Limit of Detection (Analytical Sensitivity)

The LOD for Green Spring[®] SARS-CoV-2 antigen rapid test kit is 1.3×10^3 TCID₅₀ /mL.

The LOD for Green Spring[®] SARS-CoV-2 antigen rapid test kit was established using limiting dilutions of a viral sample inactivated by gamma irradiation. The material was supplied at a concentration of 1.3×10^6 TCID₅₀ /mL. In this study, designed to estimate the LOD of the assay when using a direct nasal swab, the starting material was spiked into a volume of virus dilution in saline. An initial range-finding study was performed testing devices in triplicate using a 10-fold dilution series. At each dilution, 50 μ L samples were added to swabs and then tested using the procedure appropriate for patient nasal swab specimens. A concentration was chosen between the last dilution to give 3 positive results and the first to give 3 negative results. Using this concentration, the LOD was further refined with a 2-fold dilution series. The last dilution demonstrating 100% positivity was then tested in an additional 20 replicates tested in the same way.

HookEffect:

As part of the LOD study, the highest concentration of the sample (TCID₅₀ of 1.3×10^6 per mL) was tested.

There was no Hook effect detected.

Warnings

1. A negative result can occur if the SARS-CoV-2 virus present in the specimen is below the sensitivity of the kit.
2. Not for the screening of donated blood.
3. Do not smoke, drink, or eat in areas where specimens or kit reagents are being handled.
4. Dispose of all specimens and materials used to perform the test as biohazardous waste.
5. Handle the negative and positive controls in the same manner as patient specimens for operator protection.
6. Do not perform the test in a room with strong airflow, i.e. an electric fan or strong air-conditioning.


Explanation Of Labels

	In Vitro Diagnostic Use		Instruction for Use		CE Mark
	Batch Number		Expiry Date		Manufacturing Date
	Do not reuse		Store between 2~30°C		Keep away from Sunlight
	Keep Dry		Manufacturer		EU Authorized Representative



Shenzhen Lvshiyuan Biotechnology Co., Ltd

101,201,301, D Building, No.2 Industrial Avenue, Buxin Village, Buxin Community,
Dapeng Subdistrict Office, Dapeng New District, Shenzhen, 518120, China



Obelis s.a.

Bd General Wahis 53 1030 Brussels Belgium

Tel: +86-755-2843-8788 Fax: +86-755-2893-8800

Email: market@lsybt.com www.lsybt.com